Prelude Therapeutics (PRLD) News Today $0.96 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest UpdatePrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,940,000 shares, a growth of 18.1% from the October 15th total of 2,490,000 shares. Currently, 13.9% of the shares of the company are sold short. Based on an average trading volume of 340,700 shares, the short-interest ratio is presently 8.6 days.November 17, 2024 | marketbeat.comPrelude Therapeutics (PRLD) Receives a Sell from BarclaysNovember 9, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Q3 2024 Results and Clinical ProgressNovember 9, 2024 | msn.comPrelude Therapeutics' (PRLD) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comPrelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Shows Strong Q3 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | finance.yahoo.comOptimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial ResultsOctober 28, 2024 | markets.businessinsider.comPrelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comPrelude Therapeutics price target lowered to $1 from $3 at BarclaysOctober 27, 2024 | markets.businessinsider.comPrelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial ChallengesOctober 26, 2024 | markets.businessinsider.comPrelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International SymposiumOctober 26, 2024 | msn.comCautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market SkepticismOctober 26, 2024 | markets.businessinsider.comPrelude Therapeutics presents new data from Phase 1 trial of PRT3789October 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial PositionOctober 25, 2024 | markets.businessinsider.comPrelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumOctober 24, 2024 | globenewswire.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short InterestPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,490,000 shares, a decrease of 25.2% from the September 15th total of 3,330,000 shares. Based on an average daily volume of 282,900 shares, the short-interest ratio is currently 8.8 days. Approximately 11.7% of the company's stock are sold short.October 13, 2024 | marketbeat.comPrelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona SymposiumOctober 10, 2024 | msn.comPrelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comPrelude Therapeutics (NASDAQ:PRLD) Stock Quotes, Forecast and News SummaryOctober 1, 2024 | benzinga.comShort Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0%Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 3,330,000 shares, a growth of 37.0% from the August 31st total of 2,430,000 shares. Currently, 15.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 261,900 shares, the short-interest ratio is currently 12.7 days.September 29, 2024 | marketbeat.comHC Wainwright & Co. Upgrades Prelude Therapeutics (PRLD)September 20, 2024 | msn.comHC Wainwright Upgrades Prelude Therapeutics (NASDAQ:PRLD) to "Strong-Buy"HC Wainwright raised shares of Prelude Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday.September 20, 2024 | marketbeat.comPrelude Therapeutics (PRLD) Gets a Sell from BarclaysSeptember 16, 2024 | markets.businessinsider.comJMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)JMP Securities reissued a "market outperform" rating and set a $7.00 price target on shares of Prelude Therapeutics in a research note on Monday.September 16, 2024 | marketbeat.comBuy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial PositionSeptember 16, 2024 | markets.businessinsider.comPrelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer TreatmentSeptember 16, 2024 | msn.comPrelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell RatingSeptember 14, 2024 | markets.businessinsider.comPrelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialSeptember 13, 2024 | markets.businessinsider.comPrelude Announces Phase 1 Data Of PRT3789 Trial For Cancer Treatment; Stock FallsSeptember 13, 2024 | markets.businessinsider.comPrelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialSeptember 13, 2024 | globenewswire.comHold Rating on Prelude Therapeutics Pending PRT3789 Trial ResultsSeptember 11, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Neutral" Rating for Prelude Therapeutics (NASDAQ:PRLD)HC Wainwright reiterated a "neutral" rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research note on Tuesday.September 10, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3%Prelude Therapeutics (NASDAQ:PRLD) Trading 2.3% HigherSeptember 10, 2024 | marketbeat.comPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024September 9, 2024 | globenewswire.comPRLD Sep 2024 2.500 put (PRLD240920P00002500)August 25, 2024 | finance.yahoo.comQ3 2024 Earnings Estimate for Prelude Therapeutics Incorporated Issued By HC Wainwright (NASDAQ:PRLD)Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for Prelude Therapeutics in a note issued to investors on Thursday, August 15th. HC Wainwright analyst R. Burns now anticipates thAugust 19, 2024 | marketbeat.comPRLD Sep 2024 10.000 call (PRLD240920C00010000)August 18, 2024 | finance.yahoo.comPrelude Therapeutics Incorporated Forecasted to Post Q1 2025 Earnings of ($0.49) Per Share (NASDAQ:PRLD)Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Prelude Therapeutics in a report issued on Thursday, August 15th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per shaAugust 16, 2024 | marketbeat.comHold Rating on Prelude Therapeutics Pending Phase 1 Results of PRT3789August 16, 2024 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 46.0% in JulyPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 771,300 shares, an increase of 46.0% from the July 15th total of 528,300 shares. Currently, 3.7% of the company's shares are short sold. Based on an average trading volume of 99,000 shares, the short-interest ratio is presently 7.8 days.August 14, 2024 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Issues Earnings ResultsPrelude Therapeutics (NASDAQ:PRLD - Get Free Report) issued its earnings results on Monday. The company reported ($0.46) EPS for the quarter, hitting the consensus estimate of ($0.46).August 14, 2024 | marketbeat.comPrelude Therapeutics Reports Q2 Financial Results and Key Clinical DevelopmentsAugust 14, 2024 | msn.comPrelude Therapeutics, Incorporated: Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | finanznachrichten.deBuy Rating Affirmed for Prelude Therapeutics on Strong Pipeline and Financial PositionAugust 13, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | globenewswire.comPrelude Therapeutics Inc.August 6, 2024 | wsj.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD decreased its holdings in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) by 9.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 941,971 shares of the company's stock after selling 100,766 sharesAugust 5, 2024 | marketbeat.comWe're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn RateJuly 26, 2024 | finance.yahoo.comPrelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersJuly 9, 2024 | globenewswire.com Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide PRLD Media Mentions By Week PRLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼1.950.45▲Average Medical News Sentiment PRLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼11▲PRLD Articles Average Week Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Silence Therapeutics News Inhibrx News Zura Bio News Solid Biosciences News XBiotech News Acrivon Therapeutics News Amarin News Enanta Pharmaceuticals News Neurogene News Lexeo Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
